Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | LPL | P06858 | 10/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406802 | 1.00 | DGAT1 (0.44) | DGAT1LPLLIPGPPARAMAOA | |
| SCHEMBL22238944 | 0.84 | MAOA (0.34) | DGAT1PPARAMAOAMAOB | |
| SCHEMBL13429939 | 0.80 | DGAT1 (0.44) | DGAT1LPLLIPGFFAR1 | |
| SCHEMBL3233070 | 0.80 | LPL (0.53) | LPLLIPGPPARACA1CA2 | |
| SCHEMBL12461124 | 0.80 | DGAT1 (0.44) | DGAT1LPLLIPGPPARAFFAR1 | |
| SCHEMBL13456682 | 0.79 | DGAT1 (0.43) | DGAT1LPLLIPG | |
| SCHEMBL13429886 | 0.79 | DGAT1 (0.46) | DGAT1LPLLIPGFFAR1IRAK4 | |
| SCHEMBL20068614 | 0.79 | DGAT1 (0.56) | DGAT1LPLLIPGFFAR1CA1 | |
| SCHEMBL3220509 | 0.78 | DGAT1 (0.44) | DGAT1LPLLIPGFFAR1IRAK4 | |
| SCHEMBL13429960 | 0.77 | DGAT1 (0.44) | DGAT1LPLLIPGFFAR1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933596-B | Preparation method of tedizolid | 河北广祥制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-115792047-A | Method for detecting tedizolid phosphate intermediate related substances | 四川美域高生物医药科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114933596-A | Preparation method of tedizolid | 河北广祥制药有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-106146485-B | Method for preparing tedizolid and tedizolid crystal obtained by method | 上海迪赛诺化学制药有限公司 | 2021-04-30 | — | — | CN | claimed |
| WO-2016009401-A2 | PREPARATION OF TEDIZOLID PHOSPHATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-01-21 | — | — | WO | claimed |
| CN-113214288-B | Benzo [1,3] oxazine-oxazolidinone compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-11-03 | — | — | CN | disclosed |
| CN-114933596-B | Preparation method of tedizolid | 河北广祥制药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113214239-B | Tedizolid refining process and preparation method of tedizole phosphate | 海南通用康力制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115792047-A | Method for detecting tedizolid phosphate intermediate related substances | 四川美域高生物医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20230045135-A1 | TEDIZOLID INTERMEDIATE AND EFFICIENT PREPARATION METHOD THEREOF | NANJING CHEMPION BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-114933596-A | Preparation method of tedizolid | 河北广祥制药有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114105968-A | Method for removing palladium residue of tedizolid | 河北明吉化工科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| EP-2134721-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2009-02-19 | — | — | US | disclosed |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2009-02-19 | — | — | US | disclosed |
| WO-2009020616-A1 | ANTIMICROBIAL ORTHO-FLUOROPHENYL OXAZOLIDINONES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | DGAT1 3118/4885LPL 4201/4885LIPG 3592/4885 |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | OXA1L, OGFOD1, OLA1 | DGAT1 2252/4885LPL 2411/4885LIPG 2666/4885 |
| US-20230045135-A1 | TEDIZOLID INTERMEDIATE AND EFFICIENT PREPARATION METHOD THEREOF | DNMT3A, DNMT1, TET2 | DGAT1 4096/4885LPL 4143/4885LIPG 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.